ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2seventy bio to Present at the 5th Annual Cowen IO Next Summit

November 10, 2021 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 10, 2021--

2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the 5 th Annual Cowen IO Next Summit on November 15, at 1:15pm ET.

A webcast of the presentation will be available via the investor relations section of the 2seventy bio website for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour — to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

ADVERTISEMENT

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20211110006352/en/

CONTACT: Investors:

Elizabeth Pingpank, 617-914-8736

elizabeth.pingpank@2seventybio.comMedia:

Victoria von Rinteln, 703-599-2868

victoria.vonrinteln@2seventybio.comMorgan Adams, 774-313-9852

morgan.adams@2seventybio.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH ONCOLOGY GENERAL HEALTH HEALTH OTHER HEALTH

SOURCE: 2seventy bio, Inc.

Copyright Business Wire 2021.

PUB: 11/10/2021 04:30 PM/DISC: 11/10/2021 04:32 PM

http://www.businesswire.com/news/home/20211110006352/en